These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 23265925

  • 1. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
    Dudek AZ, Raza A, Chi M, Singhal M, Oberoi R, Mittapalli RK, Agarwal S, Elmquist WF.
    Clin Genitourin Cancer; 2013 Jun; 11(2):155-60. PubMed ID: 23265925
    [Abstract] [Full Text] [Related]

  • 2. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Blesius A, Beuselinck B, Chevreau C, Ravaud A, Rolland F, Oudard S, Escudier B.
    Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S.
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
    Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F, Groschek M, Blumenstengel K, Pühse G, Steiner T.
    World J Urol; 2011 Jun; 29(3):361-6. PubMed ID: 21461939
    [Abstract] [Full Text] [Related]

  • 7. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
    Tang SC, de Vries N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    J Pharmacol Exp Ther; 2013 Sep; 346(3):486-94. PubMed ID: 23843632
    [Abstract] [Full Text] [Related]

  • 8. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
    Verma J, Jonasch E, Allen P, Tannir N, Mahajan A.
    Cancer; 2011 Nov 01; 117(21):4958-65. PubMed ID: 21484781
    [Abstract] [Full Text] [Related]

  • 9. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
    Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H.
    Eur Urol; 2008 Dec 01; 54(6):1373-8. PubMed ID: 18692304
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.
    Chemotherapy; 2012 Dec 01; 58(6):468-74. PubMed ID: 23548259
    [Abstract] [Full Text] [Related]

  • 11. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
    Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T, Czech Renal Cancer Cooperative Group.
    Ann Oncol; 2012 Dec 01; 23(12):3137-3143. PubMed ID: 22700990
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J.
    Oncotarget; 2016 May 10; 7(19):27044-54. PubMed ID: 26894858
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
    Derbel Miled O, Dionne C, Terret C, Segura-Ferlay C, Flechon A, Neidhart EM, Negrier S, Droz JP.
    J Geriatr Oncol; 2013 Jul 10; 4(3):255-61. PubMed ID: 24070463
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Therapy for metastatic RCC--questions remain.
    Breau RH, Leibovich BC.
    Nat Rev Urol; 2009 Nov 10; 6(11):580-1. PubMed ID: 19890336
    [No Abstract] [Full Text] [Related]

  • 16. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
    Bourlon MT, Gao D, Trigero S, Clemons JE, Breaker K, Lam ET, Flaig TW.
    Cancer Med; 2016 Dec 10; 5(12):3386-3393. PubMed ID: 27758076
    [Abstract] [Full Text] [Related]

  • 17. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
    Ishihara H, Yagisawa T, Kondo T, Omae K, Takagi T, Iizuka J, Kobayashi H, Tanabe K.
    Int J Clin Oncol; 2017 Feb 10; 22(1):126-135. PubMed ID: 27549785
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
    Flörcken A, Takvorian A, Van Lessen A, Singh A, Hopfenmüller W, Dörken B, Pezzutto A, Westermann J.
    Anticancer Drugs; 2012 Mar 10; 23(3):298-302. PubMed ID: 22156795
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J, Zhu Y, Zhang C, Wang X, He H, Wang H, Wu Y, Zhou W, Shen Z.
    Urol Oncol; 2013 Nov 10; 31(8):1800-5. PubMed ID: 22658883
    [Abstract] [Full Text] [Related]

  • 20. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U.
    Oncology; 2009 Nov 10; 76(5):350-4. PubMed ID: 19321976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.